{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:52:55Z","timestamp":1784058775580,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy, especially in pediatrics, that can involve the bone marrow, skin, lymph nodes, and central nervous system (CNS). Given its variable clinical presentation, coupled with an immunohistochemistry pattern (CD4, CD56, TCF4, TCL-1, and CD123 positivity) that differs from other myeloid neoplasms, the diagnosis of BPDCN can be missed. Limited data are available to guide the treatment of pediatric BPDCN. Herein, we report a case of a pediatric patient who had BPDCN with central nervous system, orbital, and skin involvement. This patient achieved complete remission after receiving modified hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone with venetoclax and intrathecal chemotherapy. He remains disease-free 200 days after receiving a stem cell transplant. This represents the first known published pediatric case using a modified hyper-CVAD plus venetoclax regimen for treating a pediatric BPDCN patient in the frontline setting.<\/jats:p>","DOI":"10.1097\/mph.0000000000002748","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:39Z","timestamp":1693785639000},"page":"e1001-e1004","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.1097","volume":"45","author":[{"given":"Jiasen","family":"He","sequence":"first","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam B.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Connors","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Nu\u00f1ez","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres E.","family":"Quesada","sequence":"additional","affiliation":[{"name":"Department of Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roth","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McCall","sequence":"additional","affiliation":[{"name":"Division of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","article-title":"Plasmacytoid dendritic cells: physiologic roles and pathologic states","volume":"16","author":"Jegalian","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/MPH.0000000000000964","article-title":"Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review","volume":"39","author":"Kim","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","article-title":"Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications","volume":"95","author":"Jegalian","year":"2010","journal-title":"Haematologica"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"2016","author":"Sullivan","year":"2016","journal-title":"Hematology"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13256-021-02860-z","article-title":"A misdiagnosed case of blastic plasmacytoid dendritic cell neoplasm experiencing multiple recurrences who underwent allogeneic stem cell transplantation: a case report","volume":"15","author":"Salemi","year":"2021","journal-title":"J Med Case Rep"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1066896914553662","article-title":"A case report: blastic plasmacytoid dendritic cell neoplasm is misdiagnosed as breast infiltrating ductal carcinoma","volume":"23","author":"Chen","year":"2015","journal-title":"Int J Surg Pathol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/dermatopathology9040038","article-title":"A rare case of blastic plasmacytoid dendritic cell neoplasm in a child mimicking lymphoma\/leukemia cutis","volume":"9","author":"Phusuphitchayanan","year":"2022","journal-title":"Dermatopathology (Basel)"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-018-0604-6","article-title":"First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases","volume":"11","author":"Sun","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/0284186X.2017.1420229","article-title":"Complete monocular vision loss due to optic nerve involvement of blastic plasmacytoid dendritic cell neoplasm","volume":"57","author":"Chou","year":"2018","journal-title":"Acta Oncol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(21)00161-7","article-title":"Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm","volume":"8","author":"Balikov","year":"2021","journal-title":"Lancet Haematol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/ccr3.3690","article-title":"Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic\/myeloproliferative neoplasms","volume":"9","author":"Sagou","year":"2020","journal-title":"Clin Case Rep"},{"key":"R16-20250804","first-page":"Article 12","article-title":"A case report of tragaxofusp causing severe tumor lysis syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm","volume":"21","author":"Lin","year":"2020","journal-title":"Med Forum"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"e230332","DOI":"10.1136\/bcr-2019-230332","article-title":"Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia","volume":"12","author":"Khan","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J Clin Oncol"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-19-2329","article-title":"FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"26","author":"Jen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2021-150393","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in pediatric patients with tagraxofusp, a CD123-targeted therapy","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1002\/pbc.24483","article-title":"Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia","volume":"60","author":"Wright","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20250804","first-page":"100313","article-title":"Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): a case report and literature review","volume":"17","author":"Abla","year":"2022","journal-title":"Leuk Res Rep"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N Engl J Med"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1080\/10428194.2022.2090552","article-title":"Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"63","author":"Davis","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1097\/HS9.0000000000000841","article-title":"Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel","volume":"7","author":"Pagano","year":"2023","journal-title":"Hemasphere"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:30Z","timestamp":1754337870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002748","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"2023-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}